39 completed, 11 unknown, 8 terminated, 4 active not recruiting. 64 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 64 | Completed 39, Unknown 11, Terminated 8, Active not recruiting 4, Recruiting 2 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Mitoxantrone: new trials by email Literature Review of Mitoxantrone trials Research Report on Mitoxantrone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer Technetium Tc 99m Sulfur Colloid Injection, Mitoxantrone Hydrochloride Injection for Tracing - Sentinel Nodes, Breast Cancer | Phase 3 | Completed | HTA Co., Ltd. | 213 | 2024-01-02 | 2026-08-14 |
| Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children Cladribine, G-CSF, Cytarabine - Leukemia, Monocytic, Acute, Pediatric AML | Phase 2 / Phase 3 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 43 | 2021-12-01 | 2023-07-27 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage DFP-10917, Cytarabine, Azacitidine - Leukemia, Myeloid, Acute | Phase 3 | Terminated | Delta-Fly Pharma, Inc. | 167 | 2019-11-22 | 2026-01-22 |
| Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine - Relapsed/Refractory Acute Myeloid Leukemia | Phase 3 | Terminated | Cornerstone Pharmaceuticals | 200 | 2018-11-12 | 2023-02-08 |
| Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Crenolanib, Cytarabine, Mitoxantrone - Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | Phase 3 | Completed | Arog Pharmaceuticals, Inc. | 106 | 2018-08-16 | 2026-04-09 |
| A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation Gilteritinib, Cytarabine, Mitoxantrone - AML With FLT3 Mutation | Phase 3 | Completed | Astellas Pharma Inc | 276 | 2017-10-25 | 2026-09-22 |
| A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old A arm (DA-90), B arm (DAC), A arm (CLAG-M) - Acute Myeloid Leukemia | Phase 3 | Unknown | Polish Adult Leukemia Group | 582 | 2017-07-03 | 2021-10-01 |
| Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations chemotherapy (Mitoxantrone, Cytarabine), Placebo, Crenolanib - Acute Myeloid Leukemia | Phase 3 | Terminated | University of Ulm | 9 | 2016-11-17 | 2021-10-06 |
| Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Arsenic trioxide, Idarubicin, Cytarabine - Acute Promyelocytic Leukemia | Phase 3 | Completed | Technische Universität Dresden | 133 | 2016-06-01 | 2026-05-29 |
| International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia Gemtuzumab ozogamicin, Liposomal daunorubicin, Mitoxantrone - Acute Myeloid Leukaemia | Phase 3 | Active not recruiting | University of Birmingham | 700 | 2016-04-01 | 2026-06-29 |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine - Acute Myeloid Leukemia, Down Syndrome | Phase 3 | Active not recruiting | Children's Oncology Group | 280 | 2015-12-23 | 2026-08-19 |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine - Leukemia, Acute Myeloid (AML) | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | 371 | 2015-10-20 | 2025-12-04 |
| Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Arsenic Trioxide, Cytarabine, Dexamethasone - Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | Phase 3 | Active not recruiting | Children's Oncology Group | 158 | 2015-07-21 | 2026-02-18 |
| A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin - Prostate Cancer Patients | Phase 2 / Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 300 | 2015-01-01 | 2026-01-12 |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 669 | 2014-12-17 | 2026-11-13 |
| Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia DAC, CLAG, Consolidation, I HAM cycle - Acute Myeloid Leukemia | Phase 3 | Unknown | dr hab. n. med. Agnieszka Wierzbowska | 400 | 2014-02-01 | 2014-02-27 |
| A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine) - Acute Lymphoblastic Leukemia | Phase 3 | Completed | Pfizer | 326 | 2012-08-02 | 2019-01-09 |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer cabozantinib, mitoxantrone, prednisone - Prostate Cancer, Castration Resistant Prostate Cancer | Phase 3 | Terminated | Exelixis | 119 | 2012-03-01 | 2018-05-23 |
| Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Asparaginase, Bortezomib, Cytarabine - Acute Myeloid Leukemia, Leukemia Cutis | Phase 3 | Completed | National Cancer Institute (NCI) | 1645 | 2011-07-06 | 2026-06-02 |
Showing 20 of 64. Sign in to see all of them.
Leukemia, Myeloid, Acute (22) · Leukemia (15) · Lymphoma (11) · Prostatic Neoplasms (9) · Leukemia, Erythroblastic, Acute (8) · Leukemia, Monocytic, Acute (8) · Leukemia, Megakaryoblastic, Acute (7) · Leukemia, Myelomonocytic, Acute (7) · Lymphoma, Follicular (6) · Lymphoma, Large B-Cell, Diffuse (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Lymphoma, Large-Cell, Immunoblastic (5) · Lymphoma, Non-Hodgkin (5) · Myelodysplastic Syndromes (5) · Anemia, Refractory, with Excess of Blasts (4)
European Organisation for Research and Treatment of Cancer - EORTC (7) · Children's Oncology Group (5) · Pfizer (4) · M.D. Anderson Cancer Center (3) · Lymphoma Trials Office (2) · Medical Research Council (2) · NCIC Clinical Trials Group (2) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · Sanofi (2) · University of Ulm (2) · Acute Leukemia French Association (1) · Arbeitsgemeinschaft fur Internistische Onkologie (1) · Arog Pharmaceuticals, Inc. (1) · Astellas Pharma Global Development, Inc. (1)
United States (27) · Germany (17) · Canada (16) · France (16) · United Kingdom (15) · Italy (13) · Australia (11) · Belgium (11) · Netherlands (8) · Puerto Rico (7) · Spain (7) · Austria (6) · China (6) · New Zealand (6) · Poland (6)
Alan K. Burnett, MD, FRCP (2) · Franco Mandelli, MD (2) · Roel Willemze, MD, PhD (2) · Alan S. Gamis, MD, MPH (1) · Andy Haynes, MD (1) · Brenda Gibson (1) · Catherine Behar, MD (1) · Christophe Bergeron (1) · Daniel C. Betticher, MD (1) · Daniel Levitt, MD, PhD (1) · Daniel P. Petrylak, MD (1) · Denis Fiere, MD (1) · Donald S. Ernst, MD, FRCPC (1) · Else G. Heidemann, MD (1)
PMID 34596937, PMID 36815378, PMID 37267439, PMID 38295280, PMID 40294366, PMID 42085603, PMID 42668697, PMID 10604271, PMID 12239143, PMID 12419743, PMID 12947070, PMID 15353542, PMID 15470214, PMID 15637138, PMID 15761020, PMID 16136166, PMID 16333838, PMID 16622120, PMID 16782921, PMID 16888080, PMID 16932345, PMID 17039234, PMID 17252021, PMID 17315155, PMID 17339189, PMID 17407135, PMID 17611565, PMID 18025439, PMID 18349405, PMID 19130298, PMID 19242495, PMID 19291085, PMID 19826132, PMID 20038732, PMID 20378563, PMID 20407035, PMID 20451454, PMID 20625116, PMID 20888992, PMID 21131038, PMID 21502546, PMID 21690555, PMID 22649106, PMID 22743148, PMID 23321258, PMID 23471307, PMID 23538338, PMID 23723295, PMID 23863898, PMID 24127442
U10CA180886 (5), U10CA098543 (3), U10CA032102 (2), 2004 (1), 2014 (1), 2015 (1), 2017 (1), P30CA008748 (1), P30CA016672 (1), R01CA113482 (1)